RPGLIFE - RPG LifeScience.
📢 Recent Corporate Announcements
RPG Life Sciences has recommended a final dividend of ₹24 per equity share (300% of face value) for the financial year ended March 31, 2026. The company also announced the appointment of Dr. Pratit Samdani, a renowned physician, as an Additional Non-Executive Independent Director for a five-year term. This announcement follows a regulatory filing to provide financial results in a machine-readable format, confirming that there are no changes to the previously reported audited figures. The board has confirmed unmodified audit opinions for both standalone and consolidated financial statements.
- Recommended a final dividend of ₹24 per equity share of face value ₹8 (300%) for FY 2025-26.
- Appointed Dr. Pratit Samdani as Additional Non-Executive Independent Director from April 29, 2026, to April 28, 2031.
- Audited financial results for Q4 and FY26 confirmed with an unmodified opinion from statutory auditors SR BC & CO LLP.
- Resubmitted financial results in machine-readable/searchable form as per NSE request with zero changes to original data.
RPG Life Sciences has recommended a substantial final dividend of ₹24 per equity share (300% of face value) for FY 2025-26, pending shareholder approval. The company reported its audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. In a strategic move, the board appointed Dr. Pratit Samdani, a highly respected physician, as an Additional Non-Executive Independent Director for a five-year term. The company also updated its internal code for fair disclosure and insider trading monitoring.
- Recommended a dividend of ₹24 per equity share of face value ₹8, representing a 300% payout.
- Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
- Appointed Dr. Pratit Samdani as an Independent Director for a 5-year term until April 2031.
- Statutory auditors issued a report with an unmodified opinion on the company's financial statements.
- Amended the Code of Fair Disclosure and internal procedures for regulating trading by designated persons.
RPG Life Sciences has recommended a final dividend of Rs. 24 per equity share for FY 2025-26, which represents a 300% payout on the face value of Rs. 8. The company has fixed June 19, 2026, as the record date for determining shareholder eligibility for this dividend, pending AGM approval. Alongside the financial results, the board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term. The dividend is expected to be paid within 30 days of the Annual General Meeting.
- Recommended a final dividend of Rs. 24 per equity share (300% of face value)
- Fixed June 19, 2026, as the record date for dividend entitlement
- Approved audited standalone and consolidated financial results for FY 2025-26
- Appointed Dr. Pratit Samdani as Independent Director for a 5-year term until 2031
- Dividend payment to be completed within 30 days of shareholder approval at the AGM
RPG Life Sciences reported a strong Q4 FY26 with revenue growing 23.6% YoY to ₹176.9 crores and a healthy EBITDA margin of 25.6%. The Domestic Formulations business outperformed the Indian Pharma Market by 1.8 times, growing at 18.2% in Q4. A significant highlight was the API division's 144.3% growth, marking a full recovery after operations were impacted by a fire in early 2025. The company also announced a substantial final dividend of ₹24 per share for the fiscal year.
- Q4 FY26 Revenue rose 23.6% YoY to ₹176.9 crores with an EBITDA margin of 25.6%
- Domestic Formulations grew 18.2% in Q4, outpacing the Indian Pharma Market growth of 10.1%
- API division revenue surged 144.3% in Q4 FY26 following the restoration of the manufacturing facility
- Full-year FY26 revenue reached ₹707.5 crores, up 8.3% from ₹653.4 crores in FY25
- Recommended a final dividend of ₹24 per equity share (300% on face value of ₹8)
RPG Life Sciences has recommended a substantial dividend of Rs 24 per equity share (300% of face value) for the financial year 2025-26. The Board approved the audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. To strengthen its leadership, the company appointed Dr. Pratit Samdani, a renowned physician and researcher, as an Independent Director for a five-year term. Additionally, the company updated its code of conduct for fair disclosure and insider trading monitoring.
- Recommended a dividend of Rs 24 per equity share of face value Rs 8 (300% payout) for FY 2025-26.
- Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
- Appointed Dr. Pratit Samdani as Additional Non-Executive Independent Director for a 5-year term starting April 29, 2026.
- Updated the Code of fair disclosure and internal procedures for regulating and reporting trading by designated persons.
RPG Life Sciences has recommended a substantial final dividend of ₹24 per equity share (300% of face value) for the financial year 2025-26. The board approved the audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. Additionally, the company has strengthened its board by appointing Dr. Pratit Samdani, a highly respected physician and researcher, as an Additional Non-Executive Independent Director for a five-year term. This appointment is expected to bring deep clinical and research expertise to the company's strategic oversight.
- Recommended a final dividend of ₹24 per equity share of face value ₹8, representing a 300% payout.
- Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
- Appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a 5-year term until April 2031.
- The statutory auditor's report for the financial year was issued with an unmodified opinion.
- Updated the Code of Fair Disclosure and internal procedures for regulating trading by designated persons.
RPG Life Sciences Limited has scheduled its earnings conference call for Thursday, April 30, 2026, at 3:30 PM IST. The call will discuss the audited financial results for the quarter and full year ended March 31, 2026. The management team, including Managing Director Ashok Nair and CFO Amol Lone, will represent the company. This is a routine regulatory filing to inform shareholders and analysts about the upcoming performance review session.
- Earnings call scheduled for April 30, 2026, at 3:30 PM IST
- Focus on audited financial results for the period ended March 31, 2026
- Management representation by MD Ashok Nair and CFO Amol Lone
- Universal access dial-in numbers provided: +91 22 6280 1116 and +91 22 7115 8017
RPG Life Sciences has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The company's Registrar and Transfer Agent, MUFG Intime India Private Limited, confirmed that all dematerialization requests were processed within the mandated timelines. The filing ensures that physical share certificates received were mutilated, cancelled, and replaced by the depository's name in the register of members. This is a standard administrative procedure to maintain accurate shareholding records.
- Confirmed compliance under Regulation 74(5) of SEBI Regulations for the quarter ended March 31, 2026.
- Registrar MUFG Intime India confirmed processing of all dematerialization requests within prescribed timelines.
- Physical security certificates were mutilated and cancelled after verification by the depository participant.
- The name of the depositories has been substituted in the register of members as the registered owner.
RPG Life Sciences Limited has informed the stock exchanges that its trading window will be closed starting April 1, 2026. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, preceding the announcement of financial results. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the audited financial results for the year ending March 31, 2026, are declared. The specific date for the board meeting to approve these results will be communicated at a later date.
- Trading window closure effective from Wednesday, April 1, 2026.
- Closure is in anticipation of audited financial results for the year ending March 31, 2026.
- Restriction applies to all Designated Persons and their immediate relatives.
- Window will reopen 48 hours after the official declaration of the financial results.
RPG Life Sciences clarified to the NSE that its standalone and consolidated financial results for Q3 FY26 are identical because its new subsidiary, RPG Active Pharma Limited, only commenced operations on January 6, 2026. The company reported a Q3 revenue of ₹18,003 Lakhs and a Profit After Tax of ₹2,213 Lakhs. Results were impacted by a one-time exceptional charge of ₹1,108 Lakhs due to the implementation of New Labour Codes. The internal reorganization to transfer the API division is expected to be completed by February 2026 to streamline business focus.
- Q3 FY26 Revenue from operations stood at ₹18,003 Lakhs, a growth from ₹17,271 Lakhs in the previous year's corresponding quarter.
- Net Profit for the quarter was ₹2,213 Lakhs, after accounting for a ₹1,108 Lakhs exceptional expense for New Labour Code obligations.
- The company is transferring its API division to a new wholly-owned subsidiary, RPG Active Pharma Limited, incorporated on December 24, 2025.
- Insurance recovery for the January 2025 fire incident is progressing, with ₹2,050 Lakhs received against a total loss of ₹2,295 Lakhs.
- Nine-month FY26 Revenue reached ₹53,063 Lakhs with a Net Profit of ₹8,527 Lakhs.
RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.
- Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.
- PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.
- Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.
- API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.
- The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.
RPG Life Sciences reported a modest 4.2% YoY revenue growth to ₹180.0 crore for Q3 FY26, but profitability faced significant pressure. PAT declined by 19.8% to ₹27.9 crore, and EBITDA margins contracted from 30.4% to 24.0% YoY. The performance was primarily dragged down by the API segment, which saw a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite this, the Domestic Formulations business grew 8.9% and the company remains debt-free with a ₹140 crore capex plan for global expansion.
- Q3 FY26 Revenue grew 4.2% YoY to ₹180.0 Cr, while 9M FY26 Revenue reached ₹530.6 Cr (+4% YoY).
- PAT for Q3 FY26 fell 19.8% to ₹27.9 Cr, and EBITDA declined 17.7% to ₹43.2 Cr.
- API segment revenue for 9M FY26 dropped 19.4% to ₹61.7 Cr following a fire incident in a manufacturing block.
- Domestic Formulations (71% of total sales) grew 8.9% in 9M FY26, reaching ₹364.6 Cr.
- Company remains debt-free and is executing a ₹140 Cr capex for international market expansion.
RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.
- Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
- EBITDA margin remained robust at 24.0% for the quarter
- Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
- 9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
- Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores
RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.
- Board approved unaudited financial results for the quarter ended December 31, 2025
- Consolidated and standalone results for the nine-month period were submitted to exchanges
- The board meeting lasted three and a half hours, concluding at 6:30 p.m.
- Statutory auditors have provided a Limited Review Report for the period
RPG Life Sciences Limited held its board meeting on January 27, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The board reviewed both standalone and consolidated financial statements, ensuring compliance with SEBI Listing Obligations. The meeting, which lasted three and a half hours, concluded with the submission of the results and the statutory auditor's Limited Review Report. This is a routine but critical regulatory update for the third quarter of the 2025-26 fiscal year.
- Board approved unaudited standalone and consolidated financial results for Q3 FY26.
- Financial results cover the nine-month period ending December 31, 2025.
- Statutory Auditors issued a Limited Review Report on the financial statements.
- The board meeting was conducted from 03:00 p.m. to 06:30 p.m. on January 27, 2026.
Financial Performance
Revenue Growth by Segment
Domestic Formulations grew 10.1% YoY to INR 425.00 Cr in FY25. Overall revenue showed a 5-year CAGR of ~12% ending FY24, with 13% growth in FY24 and 12% in 9M FY25. Q2 FY26 revenue reached INR 181.7 Cr, a 7.6% increase over Q1 FY26.
Geographic Revenue Split
Domestic Formulations is the primary driver, contributing ~67% of total revenue in FY24. The remaining 33% is derived from International Formulations and API segments across regulated markets like the EU, Australia, and Japan.
Profitability Margins
Operating Profit Margin (OPM) improved from 19.8% in FY22 to 20.4% in FY23, 22.2% in FY24, and reached 26.3% in 9M FY25. PAT margin stood at 15.6% in Q2 FY26 (INR 28.5 Cr).
EBITDA Margin
EBITDA margin was 24.0% in Q2 FY26 (INR 43.6 Cr), up from 21.0% in Q1 FY26. The 5-year OPBIDTA CAGR is ~29%, reflecting significant operational scaling and cost optimization.
Capital Expenditure
The company has no major debt-funded capex plans. Recent investments focused on modernizing manufacturing plants and capacity enhancements. Liquidity was bolstered by monetizing surplus land at the API plant in February 2025.
Credit Rating & Borrowing
Long-term rating upgraded to [ICRA]A+ (Stable) in March 2024 from [ICRA]A (Stable). Short-term rating reaffirmed at [ICRA]A1. The company is virtually debt-free with a Total Debt/OPBDITA of 0.004x as of September 2022.
Operational Drivers
Raw Materials
Bulk drugs and intermediates for API and formulation manufacturing. Specific names not listed, but they include inputs for immunosuppressants and anti-diarrheals.
Import Sources
Significant portion of raw materials and intermediates are dependent on imports, particularly for the API segment, making margins sensitive to global price volatility.
Key Suppliers
Not specifically named in documents; however, the company monitors concentration of purchases with trading houses and related parties.
Capacity Expansion
Capacity enhancements are ongoing to support a 12% revenue CAGR. The company has modernized both manufacturing plants to secure international regulatory approvals.
Raw Material Costs
Margins are susceptible to raw material price fluctuations. Procurement strategies focus on cost rationalization and optimizing the product mix toward higher-margin international formulations.
Manufacturing Efficiency
Efficiency is driven by cost rationalization and a shift toward high-margin specialty products. Operating margins reached a peak of 26.3% in 9M FY25 due to these measures.
Logistics & Distribution
The company is expanding its field force and deploying digital solutions to enhance sales force effectiveness and distribution reach in targeted therapies.
Strategic Growth
Expected Growth Rate
12%
Growth Strategy
Growth is targeted through five pillars: Product Portfolio Rejuvenation (building chronic/specialty portfolios), Strategic Brand Asset Building (life cycle management), Customer Coverage Deepening (expanding field force), Sales Force Effectiveness, and Profitability Improvement (optimizing manufacturing).
Products & Services
Pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) for Nephrology (immunosuppressants), Gastro-intestinal (anti-diarrheal), Pain Management, Cardiovascular, Oncology, and Rheumatology.
Brand Portfolio
Not specifically listed by name, but the company relies on a few 'top brands' in the domestic market which drive the majority of revenue.
New Products/Services
Launched 12 new products in FY24 and 17 in 9M FY25. Sales from new products launched since FY19 now contribute ~25% of total domestic formulation sales.
Market Expansion
Focusing on increasing presence in existing geographies and exploring new markets after re-evaluating and deferring US market entry.
Market Share & Ranking
Holds strong market share in niche therapeutic segments like Nephrology (immunosuppressants) and Gastro-intestinal (anti-diarrheal).
Strategic Alliances
Exited biotech API segment via a slump sale to Intas Pharmaceuticals Limited in 2016 for INR 25.0 Cr to focus on core formulations.
External Factors
Industry Trends
The industry is shifting toward chronic and specialty therapies. RPGLS is positioning itself by rejuvenating its portfolio in these high-growth areas and maintaining global manufacturing compliance.
Competitive Landscape
Operates as a mid-sized player facing competition from both large Indian pharma companies and multinational corporations in regulated markets.
Competitive Moat
Moat is built on strong brand equity in specialized therapies (Nephrology) and a debt-free balance sheet providing high financial flexibility. Sustainability is supported by the RPG Group lineage.
Macro Economic Sensitivity
Sensitive to economic developments in India and changes in demand/supply conditions within the global pharmaceutical industry.
Consumer Behavior
Increasing demand for chronic disease management and specialty medicines is driving the company's shift toward these portfolios.
Geopolitical Risks
Trade barriers or regulatory changes in export markets (EU, Australia, Japan) could impact the international formulations business.
Regulatory & Governance
Industry Regulations
Strict adherence to EU GMP, WHO GMP, TGA Australia, PMDA Japan, and NDPS certifications. Susceptible to social risks related to product safety and government price controls.
Taxation Policy Impact
Subject to Indian corporate tax laws and international tax regulations for export revenue.
Legal Contingencies
No fines or penalties related to corruption or conflict of interest were reported for FY25. Secretarial audit is conducted to ensure compliance with statutory records.
Risk Analysis
Key Uncertainties
Adverse regulatory observations from health authorities could impact manufacturing and profitability. Sustained deterioration in RoCE below 16% is a key rating monitorable.
Geographic Concentration Risk
67% of revenue is concentrated in the Indian domestic market, making it sensitive to local regulatory and economic shifts.
Third Party Dependencies
Dependency on external suppliers for imported raw materials and intermediates poses a risk to margin stability.
Technology Obsolescence Risk
The company is mitigating technology risks by modernizing plants and deploying digital solutions for sales force effectiveness.
Credit & Counterparty Risk
Receivables quality is supported by a stable working capital cycle and strong liquidity, with cash and liquid investments of INR 126 Cr as of Sept 2024.